PRGOPerrigo Company plc
$15.05-26% 1Y
$15.05
$9.0252 weeks$21.46
The financials
Perrigo Company plc by the numbers
Perrigo Company plc (PRGO) reported revenue of $1.02B in Q2 2026 (quarter ended Jun 27, 2026), down 3.2% from the same quarter a year earlier. That came with a gross margin of 31% and net income of $75M (7.3% of revenue). For the full year FY2025, revenue was $4.25B (−2.8% year on year) and net income −$1.43B. Its largest product in Q2 2026 was Upper Respiratory at $178M, 22% of the disclosed total, just ahead of Skin Health at 20%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.02B | $1.06B | −3.2% |
| Gross profit | $314M | $363M | −14% |
| Operating income | $24M | $45M | −48% |
| Net income | $75M | −$8.4M | to a profit |
| Diluted EPS | $0.53 | −$0.06 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Upper Respiratory | $178M | 22% |
| Skin Health | $162M | 20% |
| Healthy Lifestyle | $158M | 20% |
| Pain And Sleep | $125M | 16% |
| Digestive Health | $116M | 14% |
| Womens Health | $65M | 8.1% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $803.1M (+7.0%)
Womens Health grew +3.3% year on yearPain And Sleep -13% year on year
Segment Latestquarter on quarteryear on year
- Upper Respiratory$178.4M$178.4Mquarter on quarter -9.6%year on year -1.6%-9.6%-1.6%
- Skin Health$161.8M$161.8Mquarter on quarter +6.5%year on year -5.0%+6.5%-5.0%
- Healthy Lifestyle$157.8M$157.8Mquarter on quarter +11%year on year +2.0%+11%+2.0%
- Pain And Sleep$124.6M$124.6Mquarter on quarter +17%year on year -13%+17%-13%
- Digestive Health$115.7M$115.7Mquarter on quarter +20%year on year -3.4%+20%-3.4%
- Womens Health$64.8M$64.8Mquarter on quarter +18%year on year +3.3%+18%+3.3%
Drug Manufacturers, Specialty & Generic
Ranks #23 of 41 by RyuScore